TY - JOUR
T1 - Adaptation to HLA-associated immune pressure over the course of HIV infection and in circulating HIV-1 strains
AU - Alves, Eric
AU - Al-Kaabi, Marwah
AU - Keane, Niamh M.
AU - Leary, Shay
AU - Almeida, Coral Ann M.
AU - Deshpande, Pooja
AU - Currenti, Jennifer
AU - Chopra, Abha
AU - Smith, Rita
AU - Castley, Alison
AU - Mallal, Simon
AU - Kalams, Spyros A.
AU - Gaudieri, Silvana
AU - John, Mina
N1 - Funding Information:
This work was funded by a National Health and Medical Research Council grant (APP1148284) awarded to SG, a grant from the Sir Charles Gairdner Hospital Foundation and PathWest awarded to SG, a UWA Research Collaboration Award (RA/1/1200/934) awarded to SG, and a National Institutes of Health-funded Tennessee Center for AIDS Research grant (P30 AI110527) awarded to SAK. EA is a recipient of an Australian Government Research Training Program Scholarship and BioZone PhD Scholarship at The University of Western Australia. SAK is supported by NIH grant R01-AI39966. The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication. The authors thank Martin Firth (University of Western Australia) for his statistical advice, and colleagues at the Vanderbilt University Medical Center, TN, USA and the Institute for Immunology and Infectious Diseases, Murdoch University, WA, Australia.
Publisher Copyright:
© 2022 Public Library of Science. All rights reserved.
PY - 2022/12
Y1 - 2022/12
N2 - Adaptation to human leukocyte antigen (HLA)-associated immune pressure represents a major driver of human immunodeficiency virus (HIV) evolution at both the individual and population level. To date, there has been limited exploration of the impact of the initial cellular immune response in driving viral adaptation, the dynamics of these changes during infection and their effect on circulating transmitting viruses at the population level. Capturing detailed virological and immunological data from acute and early HIV infection is challenging as this commonly precedes the diagnosis of HIV infection, potentially by many years. In addition, rapid initiation of antiretroviral treatment following a diagnosis is the standard of care, and central to global efforts towards HIV elimination. Yet, acute untreated infection is the critical period in which the diversity of proviral reservoirs is first established within individuals, and associated with greater risk of onward transmissions in a population. Characterizing the viral adaptations evident in the earliest phases of infection, coinciding with the initial cellular immune responses is therefore relevant to understanding which changes are of greatest impact to HIV evolution at the population level. In this study, we utilized three separate cohorts to examine the initial CD8+ T cell immune response to HIV (cross-sectional acute infection cohort), track HIV evolution in response to CD8+ T cell-mediated immunity over time (longitudinal chronic infection cohort) and translate the impact of HLA-driven HIV evolution to the population level (cross-sectional HIV sequence data spanning 30 years). Using next generation viral sequencing and enzyme-linked immunospot interferon-gamma recall responses to peptides representing HLA class I-specific HIV T cell targets, we observed that CD8+ T cell responses can select viral adaptations prior to full antibody seroconversion. Using the longitudinal cohort, we uncover that viral adaptations have the propensity to be retained over time in a non-selective immune environment, which reflects the increasing proportion of pre-adapted HIV strains within the Western Australian population over an approximate 30-year period.
AB - Adaptation to human leukocyte antigen (HLA)-associated immune pressure represents a major driver of human immunodeficiency virus (HIV) evolution at both the individual and population level. To date, there has been limited exploration of the impact of the initial cellular immune response in driving viral adaptation, the dynamics of these changes during infection and their effect on circulating transmitting viruses at the population level. Capturing detailed virological and immunological data from acute and early HIV infection is challenging as this commonly precedes the diagnosis of HIV infection, potentially by many years. In addition, rapid initiation of antiretroviral treatment following a diagnosis is the standard of care, and central to global efforts towards HIV elimination. Yet, acute untreated infection is the critical period in which the diversity of proviral reservoirs is first established within individuals, and associated with greater risk of onward transmissions in a population. Characterizing the viral adaptations evident in the earliest phases of infection, coinciding with the initial cellular immune responses is therefore relevant to understanding which changes are of greatest impact to HIV evolution at the population level. In this study, we utilized three separate cohorts to examine the initial CD8+ T cell immune response to HIV (cross-sectional acute infection cohort), track HIV evolution in response to CD8+ T cell-mediated immunity over time (longitudinal chronic infection cohort) and translate the impact of HLA-driven HIV evolution to the population level (cross-sectional HIV sequence data spanning 30 years). Using next generation viral sequencing and enzyme-linked immunospot interferon-gamma recall responses to peptides representing HLA class I-specific HIV T cell targets, we observed that CD8+ T cell responses can select viral adaptations prior to full antibody seroconversion. Using the longitudinal cohort, we uncover that viral adaptations have the propensity to be retained over time in a non-selective immune environment, which reflects the increasing proportion of pre-adapted HIV strains within the Western Australian population over an approximate 30-year period.
UR - http://www.scopus.com/inward/record.url?scp=85144777496&partnerID=8YFLogxK
U2 - 10.1371/journal.ppat.1010965
DO - 10.1371/journal.ppat.1010965
M3 - Article
C2 - 36525463
AN - SCOPUS:85144777496
SN - 1553-7366
VL - 18
JO - PLoS Pathogens
JF - PLoS Pathogens
IS - 12
M1 - e1010965
ER -